AMRX (STOCKS)
Amneal Pharmaceuticals, Inc. Class A Common Stock
$12.980000
+0.440000 (+3.51%)
Prev close: $12.540000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Chintu Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,033.54M
- Employees
- 8,100
- P/E (TTM)
- 56.54
- P/B (TTM)
- -55.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $3.02B |
| Benefits Costs and Expenses | $2.88B |
| Cost Of Revenue | $1.91B |
| Costs And Expenses | $2.88B |
| Gross Profit | $1.11B |
| Nonoperating Income/Loss | -$254.89M |
| Operating Expenses | $719.21M |
| Selling, General, and Administrative Expenses | $526.83M |
| Research and Development | $186.18M |
| Other Operating Expenses | $6.21M |
| Operating Income/Loss | $394.10M |
| Income/Loss From Continuing Operations After Tax | $127.93M |
| Income/Loss From Continuing Operations Before Tax | $139.21M |
| Income Tax Expense/Benefit | $11.28M |
| Income Tax Expense/Benefit, Current | $11.28M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | $127.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $55.88M |
| Net Income/Loss Attributable To Parent | $72.06M |
| Net Income/Loss Available To Common Stockholders, Basic | $72.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.23 |
| Diluted Earnings Per Share | $0.22 |
| Basic Average Shares | 313,367,000 |
| Diluted Average Shares | 324,805,000 |
| Assets | $3.68B |
| Current Assets | $1.91B |
| Inventory | $606.30M |
| Other Current Assets | $1.30B |
| Noncurrent Assets | $1.77B |
| Fixed Assets | $442.95M |
| Intangible Assets | $563.50M |
| Other Non-current Assets | $760.65M |
| Liabilities | $3.67B |
| Current Liabilities | $881.63M |
| Noncurrent Liabilities | $2.79B |
| Long-term Debt | $2.57B |
| Other Non-current Liabilities | $218.81M |
| Equity | -$71.33M |
| Equity Attributable To Noncontrolling Interest | -$535.00K |
| Equity Attributable To Parent | -$70.79M |
| Temporary Equity | $77.29M |
| Liabilities And Equity | $3.68B |
| Net Cash Flow From Operating Activities | $339.99M |
| Net Cash Flow From Operating Activities, Continuing | $339.99M |
| Net Cash Flow From Investing Activities | -$112.26M |
| Net Cash Flow From Investing Activities, Continuing | -$112.26M |
| Net Cash Flow From Financing Activities | -$31.53M |
| Net Cash Flow From Financing Activities, Continuing | -$31.53M |
| Exchange Gains/Losses | -$1.68M |
| Net Cash Flow | $194.52M |
| Net Cash Flow, Continuing | $196.20M |
| Comprehensive Income/Loss | $26.84M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $26.84M |
| Other Comprehensive Income/Loss | -$101.10M |
| Other Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Other Comprehensive Income/Loss Attributable To Parent | -$45.22M |